These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 38439176)
1. Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study. Shirasugi I; Onishi A; Nishimura K; Yamamoto W; Murakami K; Onizawa H; Maeda Y; Ebina K; Son Y; Amuro H; Katayama M; Hara R; Nagai K; Hiramatsu Y; Hashimoto M; Okano T; Maeda T; Hayashi S; Sendo S; Jinno S; Yamamoto Y; Yamada H; Ueda Y; Saegusa J Int J Rheum Dis; 2024 Mar; 27(3):e15097. PubMed ID: 38439176 [TBL] [Abstract][Full Text] [Related]
2. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756 [TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study. Maeda Y; Hirano T; Ebina K; Hara R; Hashimoto M; Yamamoto W; Murakami K; Kotani T; Hata K; Son Y; Amuro H; Onishi A; Jinno S; Katayama M; Kumanogoh A Rheumatol Int; 2021 Jul; 41(7):1233-1241. PubMed ID: 33903963 [TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A Rheumatology (Oxford); 2024 Nov; 63(11):3065-3073. PubMed ID: 37988163 [TBL] [Abstract][Full Text] [Related]
5. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study. Nakayama Y; Hashimoto M; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A Scand J Rheumatol; 2022 Nov; 51(6):431-440. PubMed ID: 34511031 [TBL] [Abstract][Full Text] [Related]
6. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Hayashi S; Nakano N; Tsubosaka M; Kamenaga T; Kuroda Y; Matsumoto T; Yamada H; Nishimra K; Ueda Y; Saegusa J; Kuroda R Clin Rheumatol; 2024 Nov; 43(11):3285-3292. PubMed ID: 39243280 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528 [TBL] [Abstract][Full Text] [Related]
8. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152 [TBL] [Abstract][Full Text] [Related]
9. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Nakayama Y; Watanabe R; Yamamoto W; Ebina K; Hirano T; Kotani T; Shiba H; Katayama M; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Murakami K; Murata K; Ito H; Tanaka M; Matsuda S; Morinobu A; Hashimoto M Rheumatology (Oxford); 2024 Feb; 63(2):349-357. PubMed ID: 37354495 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. Lee SW; Kim SY; Chang SH BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490 [TBL] [Abstract][Full Text] [Related]
13. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Ochi S; Sonomoto K; Nakayamada S; Tanaka Y Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462 [TBL] [Abstract][Full Text] [Related]
14. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637 [TBL] [Abstract][Full Text] [Related]
16. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4). Tanaka Y; Takeuchi T; Morita Y; Kato D; Kaneko Y; Terada W Mod Rheumatol; 2024 Mar; 34(3):453-465. PubMed ID: 37319017 [TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study. Miyazaki Y; Nakayamada S; Tanaka H; Hanami K; Fukuyo S; Kubo S; Miyagawa I; Yamaguchi A; Todoroki Y; Inoue Y; Ueno M; Tanaka Y Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38889301 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Dua AB; Ford K; Fiore S; Pappas DA; Janak JC; Blachley T; Roberts-Toler C; Emeanuru K; Kremer JM; Kivitz A Rheumatol Ther; 2023 Dec; 10(6):1753-1768. PubMed ID: 37906399 [TBL] [Abstract][Full Text] [Related]
19. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532 [TBL] [Abstract][Full Text] [Related]
20. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK; J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]